1
|
Eijkelboom AH, de Munck L, Lobbes MBI, van Gils CH, Wesseling J, Westenend PJ, Guerrero Paez C, Pijnappel RM, Verkooijen HM, Broeders MJM, Siesling S. Impact of the suspension and restart of the Dutch breast cancer screening program on breast cancer incidence and stage during the COVID-19 pandemic. Prev Med 2021; 151:106602. [PMID: 34217417 PMCID: PMC9755636 DOI: 10.1016/j.ypmed.2021.106602] [Citation(s) in RCA: 40] [Impact Index Per Article: 13.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/02/2021] [Revised: 04/09/2021] [Accepted: 05/06/2021] [Indexed: 11/27/2022]
Abstract
The COVID-19 pandemic forced the Dutch national breast screening program to a halt in week 12, 2020. In week 26, the breast program was resumed at 40% capacity, which increased to 60% in week 34. We examined the impact of the suspension and restart of the screening program on the incidence of screen-detected and non-screen-detected breast cancer. We selected women aged 50-74, diagnosed during weeks 2-35 of 2018 (n = 7250), 2019 (n = 7302), or 2020 (n = 5306), from the Netherlands Cancer Registry. Weeks 2-35 were divided in seven periods, based on events occurring at the start of the COVID-19 pandemic. Incidence of screen-detected and non-screen-detected tumors was calculated overall and by age group, cT-stage, and cTNM-stage for each period in 2020, and compared to the incidence in the same period of 2018/2019 (averaged). The incidence of screen-detected tumors decreased during weeks 12-13, reached almost zero during weeks 14-25, and increased during weeks 26-35. Incidence of non-screen-detected tumors decreased to a lesser extent during weeks 12-16. The decrease in incidence was seen in all age groups and mainly occurred for cTis, cT1, DCIS, and stage I tumors. Due to the suspension of the breast cancer screening program, and the restart at reduced capacity, the incidence of screen-detected breast tumors decreased by 67% during weeks 9-35 2020, which equates to about 2000 potentially delayed breast cancer diagnoses. Up to August 2020 there was no indication of a shift towards higher stage breast cancers after restart of the screening.
Collapse
Affiliation(s)
- Anouk H Eijkelboom
- Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Godebaldkwartier 419, 3511 DT, Utrecht, the Netherlands.
| | - Linda de Munck
- Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Godebaldkwartier 419, 3511 DT, Utrecht, the Netherlands.
| | - Marc B I Lobbes
- Department of Medical Imaging, Zuyderland Medical Center Sittard-Geleen, Dr. H. van der Hoffplein 1, 6162 BG Sittard-Geleen, the Netherlands; Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, P. Debyelaan 25, 6229 HX Maastricht, the Netherlands; GROW School for Oncology and Developmental Biology, Maastricht University, Universiteitssingel 40, 6220 ER Maastricht, the Netherlands.
| | - Carla H van Gils
- Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Universiteitsweg 100, 3584 CG Utrecht, the Netherlands.
| | - Jelle Wesseling
- Divisions of Diagnostic Oncology and Molecular Pathology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands; Department of Pathology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, the Netherlands.
| | - Pieter J Westenend
- Laboratory of Pathology, Karel Lotsyweg 145, 3318 AL Dordrecht, the Netherlands.
| | - Cristina Guerrero Paez
- Dutch Breast Cancer Society (BVN), Godebaldkwartier 363, 3511 DT Utrecht, the Netherlands.
| | - Ruud M Pijnappel
- Department of Radiology, University Medical Centre Utrecht, Heidelberglaan 100, 3584 CX Utrecht, the Netherlands.
| | - Helena M Verkooijen
- Division of Imaging and Oncology, University Medical Centre Utrecht, Heidelberglaan 100, 3584 CX Utrecht, the Netherlands.
| | - Mireille J M Broeders
- Department for Health Evidence, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, the Netherlands; Dutch Expert Centre for Screening, Wijchenseweg 101, 6538 SW Nijmegen, the Netherlands.
| | - Sabine Siesling
- Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Godebaldkwartier 419, 3511 DT, Utrecht, the Netherlands; Technical Medical Centre, University of Twente, Drienerlolaan 5, 7522 NB Enschede, the Netherlands.
| | | |
Collapse
|
2
|
Yang C, Ren J, Li B, Zhang D, Ma C, Cheng C, Sun Y, Fu L, Shi X. Identification of clinical tumor stages related mRNAs and miRNAs in cervical squamous cell carcinoma. Pathol Res Pract 2018; 214:1638-1647. [PMID: 30149901 DOI: 10.1016/j.prp.2018.07.035] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/09/2018] [Revised: 07/21/2018] [Accepted: 07/31/2018] [Indexed: 01/14/2023]
Abstract
OBJECTIVES The aim of this study is to identify the clinical tumor stage related mRNAs and miRNAs, shedding light on the potential molecular mechanisms of cervical squamous cell carcinoma (CSCC). METHODS Firstly, the mRNA and miRNA next-generation sequencing data were downloaded. Secondly, clinical tumor stage correlation analysis of mRNAs and miRNA was performed, followed by the functional enrichment analysis of all clinical tumor stage related mRNAs. Thirdly, differentially expression analysis of mRNAs and miRNA between different clinical tumor stages was performed, followed by target gene prediction of these differentially expressed miRNAs. RESULTS 3 mRNAs (PER1, PRKAB1 and PMM2) and 5 miRNAs (hsa-mir-486, hsa-mir-451, hsa-mir-424, hsa-mir-144 and hsa-mir-450a-2) were overlapped from stage 1, stage 2, stage 3 and stage 4. CONCLUSIONS Alterations of differentially expressed mRNAs and miRNAs may offer important insights into the molecular mechanisms in the pathology of CSCC.
Collapse
Affiliation(s)
- Chenggang Yang
- Gu'an Bojian Bio-Technology Co., LTD., Langfang, China; Department of BigData, Beijing Medintell Bioinformatic Technology Co., LTD., Beijing, China
| | - Jing Ren
- Department of BigData, Beijing Medintell Bioinformatic Technology Co., LTD., Beijing, China
| | - Bangling Li
- Department of BigData, Beijing Medintell Bioinformatic Technology Co., LTD., Beijing, China
| | - Dongmei Zhang
- Department of BigData, Beijing Medintell Bioinformatic Technology Co., LTD., Beijing, China
| | - Cui Ma
- Gu'an Bojian Bio-Technology Co., LTD., Langfang, China; Department of BigData, Beijing Medintell Bioinformatic Technology Co., LTD., Beijing, China
| | - Cheng Cheng
- Department of BigData, Beijing Medintell Bioinformatic Technology Co., LTD., Beijing, China
| | - Yaolan Sun
- Department of BigData, Beijing Medintell Bioinformatic Technology Co., LTD., Beijing, China
| | - Lina Fu
- Department of BigData, Beijing Medintell Bioinformatic Technology Co., LTD., Beijing, China
| | - Xiaofeng Shi
- Gu'an Bojian Bio-Technology Co., LTD., Langfang, China; Department of BigData, Beijing Medintell Bioinformatic Technology Co., LTD., Beijing, China.
| |
Collapse
|